• KOL
    • Guinea Pigs
    • Elvio Guillermo Silva
    • Elvio Guillermo Silva: Influence Statistics

      Elvio Guillermo Silva

      Elvio Guillermo Silva

      Show email address

      Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX USA | Cedars Sinai Medical Center, Los Angeles, CA, USA | Department of Pathology, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Elvio Guillermo Silva:Expert Impact

      Concepts for whichElvio Guillermo Silvahas direct influence:Guinea pigs,Serous carcinoma,Undifferentiated carcinoma,Clear cells,Low malignant potential,Cell carcinoma,Ovarian neoplasms,Endometrial polyp.

      Elvio Guillermo Silva:KOL impact

      Concepts related to the work of other authors for whichfor which Elvio Guillermo Silva has influence:Ovarian cancer,Merkel cell carcinoma,Uterine cervix,Cell tumor,Fallopian tube,Differential diagnosis,Lymph node.

      KOL Resume for Elvio Guillermo Silva

      Year
      2021

      Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX USA

      2020

      Cedars Sinai Medical Center, Los Angeles, CA, USA

      Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.

      2019

      Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

      2017

      Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA,

      2016

      *Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA †Baylor University Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX.

      Cedars-Sinai Medical Center, Los Angeles, CA, USA

      2015

      Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048

      Cedars-Sinai Medical Center, Los Angeles, CA, The University of Texas MD Anderson Cancer Center, Houston, TX

      2014

      Departments of Pathology (E.J.M., D.A.B., E.G.S.) and Laboratory Medicine Gynecologic Oncology (C.W.), Cedars-Sinai Medical Center, Los Angeles, California Lurie Center for Autism (K.S.), Massachusetts General Hospital for Children, Boston, Massachusetts Department of Pathology (E.D.E., A.M., E.G.S.) and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Pathology (A.A.R.) and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio Department of Pathology (R.A.-F.) and Laboratory Medicine, Wayne State University, Detroit, Michigan Department of Pathology (E.E.F.), PennState M.S. Hershey Medical Center, Hershey, Pennsylvania Department of Pathology (D.P.M.) and Laboratory Medicine, Instituto Nacional de Cancerologia, Mexico DF, Mexico Department of Pathology (B.D.) and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada Department of Pathology (I.K.), Korea University Anam Hospital Department of Pathology (S.R.H.), Kwandong University Cheil General Hospital and Women’s Healthcare Center, Seoul, Korea

      Department of Pathology (R.B.), University of New Mexico, Albuquerque, New Mexico Department of Gynocologic Oncology (D.G.) Department of Quantitative Bioscience (P.F.) Department of Pathology (K.V., E.S.), MD Anderson Cancer Center, Houston, Texas Department of Pathology (M.Z.), University of Vermont, Burlington, Vermont

      2013

      Baylor College of Medicine (A.D.D.V.), Texas Children’s Hospital Pavilion for Women The University of Texas MD Anderson Cancer Center (A.D.D.V., I.A.-B., E.G.S.), Houston, Texas Cleveland Clinic (A.A.R.), Cleveland, Ohio Memorial Sloan-Kettering Cancer Center (K.J.P.), New York, New York Mexican Oncology Hospital (I.A.-C.) Instituto Nacional de Cancerologia (Mexico) (J.G.C.-V.), Mexico City, Mexico University Health Network (G.R.), University of Toronto, Toronto Juravinski Hospital (D.D.), McMaster University, Hamilton, Ontario, Canada Kyoto University Hospital (Y.M.), Kyoto Shikoku Cancer Center (N.T.), Matsuyama, Japan Cheil General Hospital & Women’s Healthcare Center (S.R.H.), Kwandong University, Gangneung, Korea Cedars-Sinai Medical Center (B.A., D.B., E.G.S.), Los Angeles Long Beach Memorial Medical Center (J.K.L.R.), University of California, Long Beach, California Wayne State University (R.A.-F., F.T.), Detroit, Michigan University Cancer Care (A.S.-B.), University of Mississippi Cancer Center, Jackson, Mississippi

      Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

      2012

      University of Texas MD Anderson Cancer Center, Houston, TX, USA

      2011

      Department of Pathology (A.K.W., D.A.B., E.G.S.), Cedars-Sinai Medical Center Department of Pathology (A.K.W.), University of California, San Diego; Department of Pathology (L.W.M.), Harbor-University of California, Los Angeles, California Department of Pathology and Laboratory Medicine (J.D.S.), Washington Hospital Center, Washington, DC

      2010

      Department of Pathology (L.J., M.J.M.), National Cancer Institute, Bethesda, MD Department of Pathology (A.M., M.T.D., M.G., E.G.S.), University of Texas MD Anderson Cancer Center Ludwig Institute for Cancer Research (L.L.V.), San Pablo, Brazil Department of Pathology (G.N.), Ohio University, Columbus, OH

      2009

      Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Texas

      2008

      From the Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston

      2007

      Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

      From the Department of Anatomic Pathology, Cleveland Clinic,Cleveland, Ohio (A.G.C.-V.); Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas (A.M., M.T.D., R.B., E.G.S.), and the Department of Pathology, Ohio State University Medical Center, Columbus, Ohio (G.J.N.).

      2006

      Department of Pathology and Laboratory Medicine, M.D. Anderson Cancer Center, The University of Texas, Houston, TX

      From the Karmanos Cancer Institute (R.A.-F., I.K., S.B., D.L., F.H.S., A.R.M.), Wayne State University, and Harper University Hospital, Detroit, Michigan; Women & Infants Hospital of Rhode Island (E.S.), Brown Medical School, Providence, Rhode Island; and University of Texas M.D. Anderson Cancer Center (W.D.L.), Houston, Texas

      2005

      From the Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

      Department of Pathology, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 85, Houston, TX 77030, USA

      2004

      From the Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston TX.

      Department of Pathology, M.D. Anderson Cancer Center, Houston, TX, USA

      2003

      From the Department of Pathology (A.G.N.), University of Texas Medical School, and the Department of Pathology (M.T.D., E.G.S., A.M.), University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A.

      Division of Pathology and Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX

      Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

      2002

      Departments of Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

      From the University of Texas–Houston Health Science Center (D.G.) and the University of Texas–M.D. Anderson Cancer Center (A.M., M.T.D., E.G.S.), Houston, Texas, U.S.A.

      The University of Texas M. D. Anderson Cancer Center, Houston, TX

      2001

      From the Department of Pathology (R.V., B.P.W., A.I.F.), The University of Texas-Houston Medical School, Houston, Texas, and the Department of Pathology (E.G.S., J.Y.R., M.T.D.), The University of Texas-M.D. Anderson Cancer Center, Houston, Texas.

      Department of Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030

      2000

      Departments of Gynecologic Oncology and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, Texas.

      1999

      From the Departments of Gynecologic Oncology, Pediatrics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

      1998

      Department of Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, 77030

      University of Texas Health Science Center, the University of Texas M. D. Anderson Cancer Center, and Memorial Clinical Associates, Houston, Texas; and Birth and Family Clinic, West Edmonds, Washington.

      1997

      University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 85, Houston, Texas, 77030-4095

      1996

      Pathology,

      The University of Texas, M.D. Anderson Cancer Center, Texas, USAInonu University, Turgut Ozal Medical Center, Malatya, Turkey

      1995

      Department of Pathology (E.G.S., C.T., N.G.O.) and Department of Gynecology (M.N.), the University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.

      Rajvithi Hospital, Bangkok, Thailand; Chulalongkorn University Hospital, Bangkok, Thailand; and The University of Texas M. D. Anderson Cancer Center, Box 39, 1515 Holcombe Boulevard, Houston, Texas 77030

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Elvio Guillermo Silva is among the top experts in the world.
      Concept World rank
      ck7 ema #1
      follicular cysts endosalpingiosis #1
      pattern tumors #1
      s100 cgn #1
      itts ck5 6 #1
      mixture spindle cells #1
      clear cell hmb45 #1
      disease ecc #1
      vascular pseudoinvasion cases #1
      neuroblastomas primitive #1
      ovary genitourinary tract #1
      superficial myoinvasion lvi #1
      tamoxifen killackey #1
      lowrisk study #1
      residual disease conization #1
      cd99 melana #1
      panel hlag #1
      killackey cases #1
      epithelial tumor text #1
      necs lca #1
      smears vagina #1
      considerable biologic #1
      eld bll #1
      congenital ectodermal dysplasia #1
      disease borderline oinmts #1
      carcinoma died #1
      tumors mp #1
      frequent presence endosalpingiosis #1
      ovaries primordial follicles #1
      fallopian tube theory #1
      cases lh #1
      pattern endocervical eac #1
      notably metastatic carcinomas #1
      invasion cases #1
      29yearold black woman #1
      called pec #1
      chemotherapy salpingooophorectomy #1
      primordial follicles medulla #1
      apparent benign behavior #1
      epithelioid uterine #1
      enkephalin tumors #1
      demarcated glands #1
      vsi endometrial tumor #1
      noninvasive peritoneal implants #1
      tamoxifen reports #1
      oinmts federation gynecology #1
      neuroendocrine merkel cell #1
      receptors bcm #1
      vagina features #1
      recurrences pattern #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Elvio Guillermo Silva

      KOL-Index: 20088

      Current human papillomavirus (HPV) DNA testing using pooled probes, although sensitive, lacks specificity in predicting the risk of high-grade cervical intraepithelial neoplasia (CIN 2/3) progression. To evaluate selected HPV genotyping, viral load, and viral integration status as potential predictive markers for CIN progression, we performed HPV genotyping in formalin-fixed, paraffin-embedded cervical tissue with cervical carcinoma (29 cases) and CINs (CIN 1, 27 cases; CIN 2, 28 cases; ...

      Known for Viral Load | Oncogenic Types | Hpv 16 | Human Papillomavirus | Cervical Intraepithelial
      KOL-Index: 17708

      Yolk sac tumors (YSTs) have a variety of morphologic patterns, some of which can resemble either endometrioid adenocarcinoma (EAC) or clear cell carcinoma (CCC). Immunohistochemical staining for alpha-fetoprotein (AFP) is usually only focal and thus is not always helpful in the diagnosis of YST, and pancytokeratin (CK) is expressed by all three tumors. We studied a battery of immunohistochemical markers with specific attention to the utility of cytokeratin 7 (CK7) in differentiating YST ...

      Known for Clear Cell | Yst Ccc | Ck7 Ema | Yolk Sac Tumors | Tumor Carcinoma
      KOL-Index: 17151

      Metastasis of ovarian or peritoneal serous carcinoma to the breast and/or axillary lymph nodes is a rare event. Nevertheless, its recognition and distinction from mammary carcinoma are of great clinical importance because the treatment and prognosis differ significantly. Eighteen cases of ovarian or peritoneal serous carcinoma metastatic to the breast and/or axillary LNs from a 14-year period (1990-2003) were retrieved from our files. Clinical information was obtained from the patients' ...

      Known for Serous Carcinoma | Axillary Lymph | Metastases Breast | Metastatic Disease | Ovarian Neoplasms
      KOL-Index: 16014

      In this study, we evaluate a two-tier system for grading ovarian serous carcinoma. This system is based primarily on the assessment of nuclear atypia with the mitotic rate used as a secondary feature. The study included 50 cases of low-grade ovarian serous carcinoma and 50 cases of high-grade ovarian serous carcinoma retrieved from the files of the Department of Pathology at the University of Texas M. D. Anderson Cancer Center from a 28-year period. Cases assigned to the low-grade ...

      Known for Ovarian Serous Carcinoma | Cases Grade | Shimizu Silverberg | Nuclear Atypia | Secondary Feature
      KOL-Index: 15835

      Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis. The association of this type of tumor with undifferentiated carcinoma is rare. In this study, we present the clinicopathologic features of 25 such cases. The age of the patients ranged from 30 to 82 years (median, 51 years). At presentation, the patients had either vaginal bleeding or pelvic pain. The endometrioid carcinoma involved the endometrium in 14 cases, the ...

      Known for Undifferentiated Carcinoma | Grade Endometrioid | Epithelial Cells | Endometrium Ovary | 2 Cases
      KOL-Index: 15154

      To evaluate a commercialized in situ hybridization (ISH) assay for detecting human papillomavirus (HPV) DNA, we compared the ability of a new ISH probe, Inform HPV III (Ventana Medical Systems, Tucson, AZ), to that of PCR assays to detect HPV DNA in cervical tissue specimens with normal cervix (20 cases), cervical intraepithelial neoplasia (CIN; CIN 1, 27 cases; CIN 2, 28 cases; and CIN 3, 33 cases), and cervical carcinoma (29 cases). General HPV DNA was detected using consensus ...

      Known for Cervical Carcinoma | Situ Hybridization | Hpv Dna | Intraepithelial Neoplasia | Tissue Specimens
      KOL-Index: 14573

      Ovarian serous borderline neoplasm with noninvasive implants traditionally have been considered to be nonaggressive tumors associated with an excellent prognosis. However, in our experience, recurrences commonly develop as patients are followed over many years. Eighty cases of advanced-stage ovarian serous borderline tumor with noninvasive implants were identified; the minimum follow-up period for these cases was 5 years or until the death of the patient. The following cases were ...

      Known for Serous Borderline | Noninvasive Implants | Patients Recurrence | Ovarian Tumor | 5 Years
      KOL-Index: 14345

      We compared the efficacy of p16 and ProExC immunostaining in detecting cervical intraepithelial neoplasia (CIN) 2+ in 136 formalin-fixed, paraffin-embedded cervical tissue specimens with consensus diagnoses of normal cervix, CIN 1, CIN 2, CIN 3, and carcinoma. Diffuse staining patterns of more than half the thickness of CINs and more than 10% of carcinoma cells were scored as positive. The positivity of p16 and ProExC increased significantly with the severity of cervical lesion (P < ...

      Known for Cervical Carcinoma | Intraepithelial Neoplasia | Cin 2 Cin | Efficacy P16 | Aged Biomarkers
      KOL-Index: 13469

      Paraffin sections of formalin-fixed tumor samples from 26 patients with neuroendocrine (Merkel cell) carcinoma of the skin (NECS) were studied immunohistochemically with three monoclonal antibodies to low molecular weight keratin (MAB-K) and with antibodies to leukocyte common antigen (LCA), neurofilament (NF), neuron-specific enolase (NSE), S100 protein (S100), and chromogranin (CGN), to investigate the relative diagnostic value of these antibodies. Samples from 20 lymphomas, 10 non-oat ...

      Known for Cell Carcinoma | Nse S100 | Skin Neoplasms | Paraffin Sections | Antikeratin Antibodies
      KOL-Index: 13303

      The immunohistochemical expression pattern of p16 in biopsy samples has been useful as part of a panel to distinguish adenocarcinomas arising from the endometrium from those arising from the endocervix. However, no information is available on the expression of p16 in uterine serous carcinoma (USC) or ovarian high-grade serous carcinoma that could be used for diagnostic purposes. Here, we retrospectively analyzed the immunohistochemical expression of p16 in 11 cases of USC (5 pure and 6 ...

      Known for Uterine Serous Carcinoma | P16 P53 | Grade Serous | Tumor Cells | 11 Cases
      KOL-Index: 13205

      Ovarian steroid cell tumors, not otherwise specified (SCTs, NOS) are uncommon sex cord-stromal tumors that may be difficult to distinguish from other oxyphilic or clear-cell neoplasms. Immunohistochemical staining for inhibin, although generally useful in the diagnosis of SCTs, NOS, is not positive in every case and not all laboratories have this marker available. Recently, it has been reported that calretinin is expressed by sex cord-stromal tumors. We studied six SCTs, NOS for both ...

      Known for Calretinin Inhibin | Cell Tumors | Ovarian Steroid | Sex Cord | Differential Diagnosis
      KOL-Index: 12988

      Eighteen cases of transitional cell carcinoma (TCC) of the urinary bladder containing a micropapillary component (MPC) (> 90%, three cases; 50-90%, nine cases; < 50%, six cases) are presented. The patients' mean age was 66.6 years (range, 47-81 years) with a male predominance (male-to-female ratio of 5:1). The MPC was part of the surface noninvasive TCC in 16 cases and part of the invasive portion of the TCC in all 18 cases. Eight patients had metastases, each with a predominant (> or = ...

      Known for Micropapillary Variant | Transitional Cell Carcinoma | Urinary Bladder | Surface Mpc | Cases 50
      KOL-Index: 12812

      Although differential WT-1 expression between ovarian and uterine serous carcinoma has been discussed in the literature, there have been no studies of WT-1 expression in serous carcinomas in the peritoneum with or without concurrent serous carcinoma in an endometrial polyp. This study addresses this issue and includes a small series of uterine and ovarian serous carcinomas for comparison. Nine peritoneal serous carcinomas with coexistent serous carcinoma in an endometrial polyp, 10 ...

      Known for Serous Carcinoma | Endometrial Polyp | Peritoneal Neoplasms | Wt1 Expression | Ovarian Uterine
      KOL-Index: 12722

      BACKGROUND: Merkel cell carcinoma is a rare malignant neoplasm of the skin that most often arises in the head and neck region. Despite the innocuous appearance of the primary lesion, Merkel cell carcinoma often has an aggressive clinical course with frequent locoregional recurrences and distant metastases. We evaluated the association of the width of surgical margins and the use of postoperative radiation therapy with locoregional control and survival rates.

      METHODS: The medical records ...

      Known for Merkel Cell | Surgical Excision | Local Radiotherapy | Distant Metastases | Locoregional Control
      KOL-Index: 12719

      Recently some investigators have proposed abandoning the term ovarian serous tumor of low malignant potential (SLMP) and dividing the tumors in this category into two new groups, micropapillary serous carcinoma and atypical proliferative serous tumor, based on the presence or absence of marked epithelial proliferation with a micropapillary or cribriform pattern (MP/CP). We reviewed 99 cases of advanced stage SLMP (FIGO stages II and III) to determine whether the presence or absence of ...

      Known for Serous Tumors | Patients Recurrence | Papillary Cystadenocarcinoma | Invasive Implants | Malignant Potential

      Key People For Guinea Pigs

      Top KOLs in the world
      #1
      A LEWIS FARR
      quantitative histochemistry glucuronidase hydrolysis brain iii
      #2
      OliverH LOWRY
      folin phenol reagent protein measurement tungsten compounds
      #3
      NiraJ ROSEBROUGH
      folin phenol reagent protein measurement tungsten compounds
      #4
      RoseJ Randall
      protein measurement folin phenol reagent tungsten compounds
      #5
      Peter John Barnes
      nitric oxide chronic obstructive oxidative stress
      #6
      Jay A Nadel
      cold air plasma extravasation neurogenic inflammation

      Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX USA | Cedars Sinai Medical Center, Los Angeles, CA, USA | Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United Stat

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.